Navigation Links
GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
Date:11/15/2007

e trial's

protocol

* The full-dose regimen of GeoVax vaccines continues to be well

tolerated without any type of reaction, mild or systemic, in the

majority of participants

* CD4 T-cell responses are high in both the low and full-dose

regimens, 84% and 78% of participants

* CD8 T-cell responses are present in 42% of the full-dose

recipients and 33% of the 1/10th dose recipients.

* Antibody responses to the envelope glycoprotein (Env) increased

following the fourth vaccination, and were present in 88% of the

full-dose participants

* Delivery of the fourth vaccination increased the frequency and

magnitude of the CD8 T-cell and Antibody responses

-- In November, GeoVax filed a Form 8-K with the SEC disclosing that it

was unlikely to receive the full amount of its previously announced

$7.5 million equity placement with Pure Capital LLC ("Pure"). The

Company received $300,000 from Pure during September, but Pure appeared

to be unable to fulfill its commitment for the remaining $7.2 million.

GeoVax has already initiated contacts with alternative sources of

equity capital and preliminary discussions with prospective investors

are promising. However, the Company can provide no assurance that such

other sources of equity capital will be available on favorable terms,

if at all.

Management Commentary

Donald Hildebrand, Chief Executive Officer of GeoVax, commented, "We continue to be excited about the promise of our AIDS vaccine technology. We are particularly encouraged by the recent $15 million grant award from the NIH, which we view as a strong validation of the prospects for our vaccine. We also are very pleased with the additional positive results we've seen for both our full and 1/10th dose groups in our Phase I hum
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
4. Biopure Announces 2007 Third Quarter Financial Results
5. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
6. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
7. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
8. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
9. Pharmacopeia Announces Third Quarter 2007 Financial Results
10. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
11. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... WASHINGTON, Dec. 6, 2011  BodyMedia, the leading developer ... Qualcomm Life, a wholly owned subsidiary of Qualcomm ... BodyMedia FIT ™ LINK Armband ... BodyMedia Armband users to share wireless health data, ...
... 6, 2011  Echo Therapeutics, Inc. (Nasdaq: ECTE ... a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system ... today announced a registered direct equity financing of approximately ... of one share of its common stock and a ...
Cached Medicine Technology:BodyMedia Plans to Join Qualcomm Life's Wireless Health 2net Ecosystem 2BodyMedia Plans to Join Qualcomm Life's Wireless Health 2net Ecosystem 3BodyMedia Plans to Join Qualcomm Life's Wireless Health 2net Ecosystem 4Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing 2Echo Therapeutics Announces Pricing of $5.4 Million Registered Direct Equity Financing 3
(Date:7/9/2014)... types of cancer sends the protein factories in our ... uncontrolled growth, new research suggests. , Scientists at The ... responsible for ratcheting up activity of the endoplasmic reticulum ... blocks cancer cells need to keep growing. , A ... the flow of messages to the endoplasmic reticulum telling ...
(Date:7/9/2014)... that fecal transplantation is effective and safe for treating ... the result of a study led by Colleen Kelly, ... Medicine at The Women,s Medicine Collaborative. The study and ... print in the American Journal of Gastroenterology . ... , has increased to epidemic proportions over the past ...
(Date:7/9/2014)... There has been a sharp increase in the ... using MyChart, the online, interactive service that allows patients ... healthcare providers, schedule appointments, and renew prescriptions. , Over ... MyChart each year increased five-fold, while the ... 10-fold, according to a study by Dr. David ...
(Date:7/9/2014)... Allergy and Infectious Diseases (NIAID), part of the ... clinical trial of CRS3123, an investigational oral antibiotic ... C. difficile ) infection. CRS3123 (previously known as ... difficile growth while sparing normal intestinal bacteria. , ... 30 healthy men and women ages 18 to ...
(Date:7/9/2014)... , , , , , ... , , , , , ... binaural recording using KEMAR, the weapon was an SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm from the bullet... ... , , , , ... , , , , , ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... Oct. 24 NetSuite Inc., a ... suites that provide,Accounting/ERP (Enterprise Resource Planning), ... for small and medium-sized,businesses and divisions ... NetSuite,partners and solution providers have introduced, ...
... THOR ), a world leader in products to treat,cardiovascular ... for the third quarter of fiscal 2007 on Thursday, ... call to discuss its financial,results and operating activities open ... (11:30 a.m., Eastern Daylight Time), Thursday,November 1, hosted by ...
... Cancer Prevention Expert and First Hispanic President ... Communications Expert Marion E. Morra to,Lead Volunteer Board ... American Cancer,Society, the nation,s largest voluntary health organization, ... Board of Directors during its,annual meeting held this ...
... 25 3M and,Zargis Medical Corp., a spin-off ... a majority-owned subsidiary of Speedus Corp. (Nasdaq: ... involving Zargis,heart sound analysis software and 3M Littmann,s ... support 3M in its efforts to develop a,next-generation ...
... (E) Executive Director, ... American Public Health Association, WASHINGTON, Oct. 25 ... House of Representatives,today to support legislation to reauthorize the Children,s ... points of,opposition. They,ve come up with a plan that even ...
... October 25, 2007 - Postmenopausal women are at ... the chronic health conditions associated with obesity become ... of Obstetric, Gynecologic, & Neonatal Nursing reviews the ... that are relevant to postmenopausal women. The article ...
Cached Medicine News:Health News:NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 2Health News:NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 3Health News:NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 4Health News:NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 5Health News:NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 6Health News:NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality 7Health News:Thoratec Schedules Third Quarter Conference Call, Webcast 2Health News:New Volunteers Selected to Lead American Cancer Society 2Health News:New Volunteers Selected to Lead American Cancer Society 3Health News:New Volunteers Selected to Lead American Cancer Society 4Health News:New Volunteers Selected to Lead American Cancer Society 5Health News:New Volunteers Selected to Lead American Cancer Society 6Health News:3M and Zargis Announce Global Marketing Alliance 2Health News:3M and Zargis Announce Global Marketing Alliance 3Health News:3M and Zargis Announce Global Marketing Alliance 4
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
Inquire...
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Rapid latex slide agglutination assay for the qualitative and semi-quantitative determination of Rheumatoid Factors in human serum....
Medicine Products: